Non-Hodgkin Lymphoma

Andrew M. Evens, DO, MSc, discusses the approval of 3 new regimens and how they have reformed the treatment paradigm of relapsed/refractory diffuse-large B-cell lymphoma.

Kami Maddocks, MD, discusses the significance of the selinexor approval in the diffuse large B-cell lymphoma treatment paradigm, emerging strategies that seek to address unmet needs, and remaining sequencing questions.

John M. Pagel, MD, PhD, discusses the utility of rituximab with etoposide, doxorubicin, cyclophosphamide, vincristine, and prednisone in double- and triple-hit lymphoma.

Alan P. Z. Skarbnik, MD, discusses future combination therapies with tazemetostat in follicular lymphoma.

BTK inhibitors have transformed the treatment of patients with Waldenström macroglobulinemi; with 4 agents under examination in the space, selection will depend on availability, toxicity, convenience, and cost.

Alan P. Z. Skarbnik, MD, highlights the approval of tazemetostat in relapsed/refractory follicular lymphoma.

Connie L. Batlevi, MD, PhD, discusses the role of active surveillance in advanced​-stage follicular lymphoma. 

John M. Burke, MD, discusses risk stratifications strategies in follicular lymphoma. 

Andre Goy, MD, MS, discusses how matching the right treatment with the right patient resides at the heart of precision medicine, but with continued interest in pursuing the molecular milieu of cancers, precision medicine has the potential to better inform pre- and post-cancer interventions as well.

Despite efforts to advance the precision oncology portfolio for patients with diffuse large B-cell lymphoma by categorizing subtypes of the molecularly heterogenous disease, developing treatment routes for these alternate forms presents an uphill battle.

Connie L. Batlevi, MD, PhD, discusses emerging therapies in follicular lymphoma.

Alan P. Z. Skarbnik, discusses ongoing research with PI3​K inhibitors in follicular lymphoma. 

John M. Burke, MD, discusses treatment options in relapsed/refractory follicular lymphoma.

The triplet regimen of atezolizumab, obinutuzumab, and venetoclax demonstrated encouraging activity and safety in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma.

Shuo Ma, MD, PhD, discusses the utility of BTK inhibitors in relapsed/refractory chronic lymphocytic leukemia.

Erlene Seymour, MD, discusses the progression-free survival benefit with acalabrutinib with or without obinutuzumab in chronic lymphocytic leukemia.

Kami J. Maddocks, MD, discusses ongoing sequencing challenges in diffuse large B-cell lymphoma.

John M. Burke, MD, discusses the potential benefits of time-limited therapy with BTK inhibitors in B-cell malignancies.

Brian T. Hill, MD, PhD, discusses the impact of recent regulatory approvals in relapsed/refractory diffuse large B-cell lymphoma.

The investigational CAR T-cell product AUTO3 in combination with pembrolizumab was found to have a tolerable safety profile and elicit durable complete responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

The FDA has granted a priority review to a supplemental new drug application for crizotinib in the treatment of pediatric patients with ALK-positive relapsed/refractory systemic anaplastic large cell lymphoma.

Christopher Pleyer, MD, discusses the phase 2 trial examining fludarabine plus ibrutinib in CLL and SLL, the next steps for the research, and where future efforts should be focused.

The combination of the investigative PD-1 inhibitor camrelizumab plus the antiangiogenic agent apatinib led to early signals of clinical activity in patients with relapsed/refractory peripheral T-cell lymphoma, warranting further study.

A biologics license application has been submitted to the FDA for loncastuximab tesirine for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Jeffrey Zonder, MD, discusses the ZUMA-2 trial in mantle cell lymphoma and the ZUMA-5 trial in indolent non-Hodgkin lymphoma.